Final results of the LUCENT-3 open-label extension in ulcerative colitis (316 entered; 182 completed): among week-52 maintenance remitters, 77.7% were in clinical remission at week 212 (observed cases), with no new safety signals over 4 years of mirikizumab.
RCTn = 316
Sands et al. Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study